The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials
<h3>Introduction</h3><p dir="ltr">Myocardial infarction (MI) is associated with a significant post-event inflammatory response which further contributes to post-MI prognosis. Colchicine, an anti-inflammatory agent, exhibits potential benefits in various cardiovascular con...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513554973982720 |
|---|---|
| author | Ayesha Younas (7114868) |
| author2 | Zainab Awan (20151435) Tehreem Khan (20151438) Samay Mehta (17789705) Aqsa Munir (9073801) Hafsa Arshad Azam Raja (20151441) Hritvik Jain (19757091) Ahmed Raza (170325) Ayesha Sehar (20151444) Raheel Ahmed (450330) Abdulqadir J. Nashwan (11659453) |
| author2_role | author author author author author author author author author author |
| author_facet | Ayesha Younas (7114868) Zainab Awan (20151435) Tehreem Khan (20151438) Samay Mehta (17789705) Aqsa Munir (9073801) Hafsa Arshad Azam Raja (20151441) Hritvik Jain (19757091) Ahmed Raza (170325) Ayesha Sehar (20151444) Raheel Ahmed (450330) Abdulqadir J. Nashwan (11659453) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ayesha Younas (7114868) Zainab Awan (20151435) Tehreem Khan (20151438) Samay Mehta (17789705) Aqsa Munir (9073801) Hafsa Arshad Azam Raja (20151441) Hritvik Jain (19757091) Ahmed Raza (170325) Ayesha Sehar (20151444) Raheel Ahmed (450330) Abdulqadir J. Nashwan (11659453) |
| dc.date.none.fl_str_mv | 2025-01-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2024.102878 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_effect_of_colchicine_on_myocardial_infarction_An_updated_systematic_review_and_meta-analysis_of_randomized_controlled_trials/27643104 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Public health Colchicine Inflammation MI Myocardial infarction Cardiovascular death Anti-inflammatories Outcomes CRP |
| dc.title.none.fl_str_mv | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Introduction</h3><p dir="ltr">Myocardial infarction (MI) is associated with a significant post-event inflammatory response which further contributes to post-MI prognosis. Colchicine, an anti-inflammatory agent, exhibits potential benefits in various cardiovascular conditions such as coronary artery disease, pericarditis and atrial fibrillation. This meta-analysis predominantly aimed to provide an up-to-date evaluation of the efficacy and safety of colchicine in reducing adverse cardiovascular events in patients following acute MI.</p><h3>Methods</h3><p dir="ltr">A Comprehensive search was conducted on PubMed, Cochrane Library, Scopus, Google Scholar and clinicaltrials.gov for randomized controlled trials (RCTs) investigating the effect of colchicine on patients with MI from inception till May 2024. Our primary outcome was a composite of adverse cardiovascular events, while secondary outcomes included all-cause mortality, incidence of stroke, incidence of cardiac arrest, hospitalization urgency, incidence of recurrent MI, adverse gastrointestinal events and levels of high-sensitivity C - reactive protein (Hs-CRP). Risk ratios (RR) and mean differences (MD) were pooled under the random-effects model.</p><h3>Results</h3><p dir="ltr">Eleven trials with 7161 patients were included in our analysis out of which 3546 (49.51 %) were allocated to colchicine and 3591 (50.14 %) received placebo. Colchicine demonstrated statistically significant reduction in the composite of adverse cardiovascular events (RR = 0.75, 95 % CI: 0.60-0.94, P = 0.01, I<sup>2</sup> = 47 %), and hospitalization urgency (RR = 0.46, 95 % CI: 0.31-0.68, P = 0.0001, I<sup>2</sup> = 0 %) but statistically significant increment in adverse gastrointestinal events (RR = 1.86, 95 % CI: 1.14-3.02, P = 0.01, I<sup>2</sup> = 79 %). However, all-cause mortality (RR = 1.00, 95 % CI: 0.72-1.39, P = 0.98, I<sup>2</sup> = 0 %), incidence of cardiac arrest (RR = 0.81, 95 % CI: 0.33-1.95, P = 0.63, I<sup>2</sup> = 0), incidence of stroke (RR = 0.45, 95 % CI: 0.17-1.19, P = 0.11, I<sup>2</sup> = 36 %), incidence of recurrent MI (RR = 0.78, 95 % CI: 0.57-1.06, P = 0.11, I<sup>2</sup> = 11 %) and the levels of hs-CRP (MD= -0.87, 95 %CI: -1.80-0.06, P=0.07, I<sup>2</sup>=67 % remained comparable across the two groups.</p><h3>Conclusion</h3><p dir="ltr">The use of colchicine post-MI reduces the composite of adverse cardiovascular events, and hospitalization urgency but increases adverse gastrointestinal events. However, colchicine does not impact all-cause mortality, cardiac arrest, stroke incidence, incidence of recurrent MI and the levels of hs-CRP. Large scale multicenter RCTs especially with longer follow-up duration are warranted to validate these findings.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102878" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102878</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a408f2d4ba7002b101512822719fb59c |
| identifier_str_mv | 10.1016/j.cpcardiol.2024.102878 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/27643104 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trialsAyesha Younas (7114868)Zainab Awan (20151435)Tehreem Khan (20151438)Samay Mehta (17789705)Aqsa Munir (9073801)Hafsa Arshad Azam Raja (20151441)Hritvik Jain (19757091)Ahmed Raza (170325)Ayesha Sehar (20151444)Raheel Ahmed (450330)Abdulqadir J. Nashwan (11659453)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesHealth sciencesEpidemiologyPublic healthColchicineInflammationMIMyocardial infarctionCardiovascular deathAnti-inflammatoriesOutcomesCRP<h3>Introduction</h3><p dir="ltr">Myocardial infarction (MI) is associated with a significant post-event inflammatory response which further contributes to post-MI prognosis. Colchicine, an anti-inflammatory agent, exhibits potential benefits in various cardiovascular conditions such as coronary artery disease, pericarditis and atrial fibrillation. This meta-analysis predominantly aimed to provide an up-to-date evaluation of the efficacy and safety of colchicine in reducing adverse cardiovascular events in patients following acute MI.</p><h3>Methods</h3><p dir="ltr">A Comprehensive search was conducted on PubMed, Cochrane Library, Scopus, Google Scholar and clinicaltrials.gov for randomized controlled trials (RCTs) investigating the effect of colchicine on patients with MI from inception till May 2024. Our primary outcome was a composite of adverse cardiovascular events, while secondary outcomes included all-cause mortality, incidence of stroke, incidence of cardiac arrest, hospitalization urgency, incidence of recurrent MI, adverse gastrointestinal events and levels of high-sensitivity C - reactive protein (Hs-CRP). Risk ratios (RR) and mean differences (MD) were pooled under the random-effects model.</p><h3>Results</h3><p dir="ltr">Eleven trials with 7161 patients were included in our analysis out of which 3546 (49.51 %) were allocated to colchicine and 3591 (50.14 %) received placebo. Colchicine demonstrated statistically significant reduction in the composite of adverse cardiovascular events (RR = 0.75, 95 % CI: 0.60-0.94, P = 0.01, I<sup>2</sup> = 47 %), and hospitalization urgency (RR = 0.46, 95 % CI: 0.31-0.68, P = 0.0001, I<sup>2</sup> = 0 %) but statistically significant increment in adverse gastrointestinal events (RR = 1.86, 95 % CI: 1.14-3.02, P = 0.01, I<sup>2</sup> = 79 %). However, all-cause mortality (RR = 1.00, 95 % CI: 0.72-1.39, P = 0.98, I<sup>2</sup> = 0 %), incidence of cardiac arrest (RR = 0.81, 95 % CI: 0.33-1.95, P = 0.63, I<sup>2</sup> = 0), incidence of stroke (RR = 0.45, 95 % CI: 0.17-1.19, P = 0.11, I<sup>2</sup> = 36 %), incidence of recurrent MI (RR = 0.78, 95 % CI: 0.57-1.06, P = 0.11, I<sup>2</sup> = 11 %) and the levels of hs-CRP (MD= -0.87, 95 %CI: -1.80-0.06, P=0.07, I<sup>2</sup>=67 % remained comparable across the two groups.</p><h3>Conclusion</h3><p dir="ltr">The use of colchicine post-MI reduces the composite of adverse cardiovascular events, and hospitalization urgency but increases adverse gastrointestinal events. However, colchicine does not impact all-cause mortality, cardiac arrest, stroke incidence, incidence of recurrent MI and the levels of hs-CRP. Large scale multicenter RCTs especially with longer follow-up duration are warranted to validate these findings.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102878" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102878</a></p>2025-01-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2024.102878https://figshare.com/articles/journal_contribution/The_effect_of_colchicine_on_myocardial_infarction_An_updated_systematic_review_and_meta-analysis_of_randomized_controlled_trials/27643104CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/276431042025-01-01T00:00:00Z |
| spellingShingle | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials Ayesha Younas (7114868) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Public health Colchicine Inflammation MI Myocardial infarction Cardiovascular death Anti-inflammatories Outcomes CRP |
| status_str | publishedVersion |
| title | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials |
| title_full | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials |
| title_short | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials |
| title_sort | The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Public health Colchicine Inflammation MI Myocardial infarction Cardiovascular death Anti-inflammatories Outcomes CRP |